rs17465637 — MIA3

Intronic variant in MIA3/TANGO1 affecting collagen secretion and vascular smooth muscle cell behavior, with well-replicated association with coronary artery disease risk

See your personal result for MIA3

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

MIA3/TANGO1 — The Arterial Collagen Gatekeeper

Deep within the wall of every coronary artery, a molecular crane called TANGO111 TANGO1
Transport ANd Golgi Organization protein 1, encoded by the MIA3 gene on chromosome 1q41 performs a task that conventional COPII vesicles cannot: loading oversized collagen fibers — rigid triple-helical rods far too large for standard secretory vesicles — onto expanding membrane carriers for export from the endoplasmic reticulum (ER) to the extracellular matrix. The rs17465637 variant, nestled in intron 4 of MIA3, is one of the earliest and most robustly replicated GWAS hits for coronary artery disease (CAD). It was discovered by Samani et al. in 200722 Samani et al. in 2007
WTCCC and German Myocardial Infarction Family Study combined analysis and has since been confirmed in cohorts spanning Europe, North America, East Asia, and South Asia.

The Mechanism

MIA3/TANGO1 sits at ER exit sites (ERES)33 ER exit sites (ERES)
specialized membrane domains where secretory cargo is loaded into transport carriers and assembles into rings that enclose COPII coat proteins, creating a sub-compartment dedicated to packaging and exporting fibrillar collagens — including collagens I, II, III, IV, VII, and IX, and apolipoprotein B. Its SH3-like domain in the ER lumen binds collagens via the collagen chaperone HSP47; its cytoplasmic proline-rich domain (PRD) coordinates with the COPII machinery to initiate tubular carriers large enough for bulky cargo.

In the vascular wall, this matters in two distinct ways. First, MIA3 controls the mechanical integrity of the arterial wall by governing collagen secretion in smooth muscle cells and fibroblasts — reduced MIA3 function impairs the structural collagen scaffold that keeps plaques stable. Second, and paradoxically, MIA3 expression is elevated in proliferative vascular smooth muscle cells (VSMCs)44 MIA3 expression is elevated in proliferative vascular smooth muscle cells (VSMCs)
Frontiers in Endocrinology, 2021, and knockdown of MIA3 reduces VSMC proliferation, migration, and inflammation. This dual role — structural collagen support vs. pro-proliferative signaling — explains why altered MIA3 expression at either extreme can promote atherosclerosis: too little disrupts plaque stability, too much accelerates neointimal thickening and luminal narrowing.

The rs17465637 variant lies in an intron and does not change the protein directly. Its effect is presumed to be regulatory — altering MIA3 splicing efficiency, transcription factor binding, or expression level in vascular tissues — but the precise molecular mechanism remains under investigation. A parallel molecular network has been characterized: ADTRP (Androgen-Dependent TFPI-Regulating Protein)55 ADTRP (Androgen-Dependent TFPI-Regulating Protein)
another CAD GWAS locus on chromosome 6 positively regulates MIA3/TANGO1 expression through a PIK3R3 → AKT signaling cascade, linking androgen signaling, coagulation regulation, and collagen trafficking in endothelial cells — the same cells where monocyte adhesion initiates atherosclerotic plaque formation.

The Evidence

The evidence for rs17465637 is unusually robust for a GWAS intronic variant. The original discovery by Samani et al. (2007)66 Samani et al. (2007)
Genome-wide association analysis of coronary artery disease, Nature Genetics in a combined analysis of the Wellcome Trust Case Control Consortium and German MI Family Study identified the C allele with OR 1.20 (95% CI 1.12–1.30) for CAD in Europeans. This was replicated in the American Caucasian Cleveland Genebank77 American Caucasian Cleveland Genebank
PMC3115468, where the A allele (absence of the risk C allele) showed a protective effect of OR 0.75 (95% CI 0.62–0.91, P=0.003) against myocardial infarction.

Trans-ethnic replication is particularly compelling. A 2013 meta-analysis88 A 2013 meta-analysis
PMID 24125424 of five Asian cohorts totaling 7,263 CAD patients and 8,347 controls confirmed OR 1.11 (P=4.97×10⁻⁵), formally establishing rs17465637 as a cross-ancestry CAD risk locus. A prospective follow-up study showed that the C allele predicted subsequent cardiovascular events99 the C allele predicted subsequent cardiovascular events
PMID 21984477 not only in healthy controls, but also in patients with established CAD — suggesting ongoing biological risk rather than a one-time susceptibility signal.

One Pakistani study reported an additional finding: each C allele was associated with a 10.2 mg/dL increase in serum triglycerides1010 each C allele was associated with a 10.2 mg/dL increase in serum triglycerides
P=0.01, suggesting MIA3's role in ApoB trafficking from the ER may partially explain its cardiovascular effects through lipid metabolism, since ApoB is the structural protein of VLDL and LDL particles.

Practical Actions

Because rs17465637 is an intronic variant with an incompletely understood regulatory mechanism, there is no single gene-product intervention (such as supplementing an enzyme cofactor). The clinical value of knowing your genotype lies in risk stratification and targeted monitoring.

CC homozygotes carry approximately two copies of the risk allele and represent the majority genotype (~55% of Europeans). AC heterozygotes carry one copy. Only AA homozygotes (~7% of Europeans) carry the lower-risk, protective genotype. All non-AA genotypes benefit from earlier and more comprehensive cardiovascular monitoring — specifically coronary artery calcium (CAC) scoring as a sub-clinical atherosclerosis screen, and fasting lipid panels with attention to triglycerides given the documented lipid effect of the C allele.

The evidence that rs17465637 participates in a 27-locus genetic risk score that predicts statin benefit in primary prevention means that knowing your MIA3 genotype can help inform discussions about the timing of lipid-lowering therapy — particularly in the borderline-risk range where clinical guidelines allow physician discretion.

Interactions

MIA3/TANGO1 is regulated upstream by ADTRP (rs3825807 on chromosome 6p24), which activates MIA3 expression through a PIK3R3 → AKT cascade. Individuals carrying risk alleles at both loci may have compounded disruption of endothelial cell homeostasis and collagen trafficking. The literature does not yet provide quantitative compound-genotype OR estimates for rs17465637 and rs3825807 combined, so this interaction should be interpreted as pathway-level context rather than a confirmed additive risk calculation.

The collagen-secretion pathway connects MIA3 to rs12722 (COL5A1), which affects collagen V structure and arterial wall compliance. Reduced MIA3 function plus structurally altered collagen V could theoretically compound effects on arterial stiffness and plaque vulnerability, but direct interaction data are lacking in the current literature.

Genotype Interpretations

What each possible genotype means for this variant.

AA Protective Genotype Normal

Lowest MIA3-related coronary artery disease risk

You carry two copies of the A allele at rs17465637, which is the minor allele at this position. About 7% of people of European ancestry share this genotype. Studies consistently show that the A allele is protective against coronary artery disease and myocardial infarction relative to the C allele — the American Caucasian Cleveland Genebank study found an odds ratio of 0.75 for myocardial infarction in A allele carriers. Your MIA3/TANGO1-related CAD risk from this variant is at the lowest end of the population distribution.

AC One Risk Allele Intermediate

Moderately elevated coronary artery disease risk from one C allele

The rs17465637 C allele is thought to alter MIA3/TANGO1 expression or splicing in vascular tissues, affecting collagen secretion from the ER and the behavior of vascular smooth muscle cells. The association with approximately 10.2 mg/dL higher triglycerides per C allele also suggests effects on ApoB-containing lipoprotein trafficking — a function MIA3 performs at the same ER exit sites where it loads collagen. One C allele represents a meaningful but manageable risk increment; knowing it exists allows targeted earlier detection of subclinical atherosclerosis.

CC Two Risk Alleles High Risk

Highest MIA3-related coronary artery disease risk — proactive monitoring warranted

The CC genotype at rs17465637 likely alters MIA3/TANGO1 expression in vascular tissue, affecting two distinct but related processes: the mechanical integrity of the coronary artery wall through collagen secretion from smooth muscle cells, and the proliferative and migratory behavior of VSMCs that drives plaque growth and neointimal thickening. The additional association with elevated triglycerides (approximately 20 mg/dL above AA carriers) through altered ApoB-containing lipoprotein assembly from the ER represents a second cardiovascular pathway.

Importantly, this variant is one of 27 loci comprising a validated CAD genetic risk score that has been shown to both predict incident cardiovascular events and identify which individuals at borderline clinical risk derive the most benefit from statin therapy in primary prevention. For CC homozygotes with otherwise intermediate conventional risk, this genotype can serve as a tiebreaker toward earlier lipid management. The variant is common enough (~55% of Europeans are CC) that its clinical significance is best interpreted alongside overall polygenic risk and conventional risk factors rather than in isolation.